title: When are signal transduction targeted therapies acting as immunotherapy?
authors: a Massachusetts General Hospital Cancer Center ; Boston , MA , USA.
authors: Keith T
authors: KT
authors: Flaherty
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D048493:Proto-Oncogene Proteins B-raf
keywords: BRAF inhibitor; interleukin-2; ipilimumab; melanoma; synergy